期刊文献+

决明子与罗苏伐他汀联合治疗高脂血症的疗效观察 被引量:5

下载PDF
导出
摘要 目的观察决明子与罗苏伐他汀联合治疗高脂血症的疗效和安全性。方法选择高脂血症患者160例,将其随机分为A、B2组,各80例。A组服用罗苏伐他汀5mg,每晚1次。B组在A组治疗基础上加用炒黄决明子50g,水煎服,早晚各1次。均治疗1个月后,抽血检验血脂,比较2组的治疗效果。结果 B组三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)显效率均高于A组,差异有统计学意义(P<0.05)。与治疗前比较,2组TC、TG、LDL-C降低,HDL-C升高,差异均有统计学意义(P<0.01);2组间变化率比较差异有统计学意义(P<0.05)。结论决明子与罗苏伐他汀联合治疗高脂血症效果满意。
出处 《临床合理用药杂志》 2010年第18期79-80,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献2

二级参考文献8

  • 1Hatch GN.Rosuvastatin.Current opinion in cardiovascular, pulmonary and renal investigation[].Drugs.2000
  • 2Graul A,Castaner J.ZD-4522.Hypolipidemic, HMG-CoA reductase inhibitor[].Drugs of the Future.1999
  • 3Olsson A,Pears J,Mckellar J,et al.Effect of rosuvastatin on Low-density lipoprotein cholesterol in patients with hypercholesterolemioa[].The American Journal of Cardiology.2001
  • 4Davidson M,Ma P,Stein E,et al.Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type lla or llb hypercholesterolemia[].The American Journal of Cardiology.2002
  • 5Knopp RH.Drug treatment of lipid disorders[].The New England Journal of Medicine.1999
  • 6Watanabe M,Koike H,Ishiba T,et al.Synthesis and biological activity of methanesulfonamide pyrimidine-and N-methanesulfonyl pyrole-substi tuted 3,5-dihydroxy-6-heptenoates, a novel series of HMGCoA reductase inhibitors[].Bioorganic and Medicinal Chemistry.1997
  • 7Carswell Cl,Plosber GL,Jarvis B.Rosuvastatin[].Drugs.2002
  • 8Martin PD,Dane AL,Nwose D,et al.No effect of age and gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor[].Journal of Clinical Pharmacology.2002

共引文献8

同被引文献196

引证文献5

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部